CZ5498A3 - Nové inhibitory farnesyl-transferázy, způsob jejich přípravy a farmaceutické kompozice tyto inhibitory obsahující - Google Patents

Nové inhibitory farnesyl-transferázy, způsob jejich přípravy a farmaceutické kompozice tyto inhibitory obsahující

Info

Publication number
CZ5498A3
CZ5498A3 CZ9854A CZ5498A CZ5498A3 CZ 5498 A3 CZ5498 A3 CZ 5498A3 CZ 9854 A CZ9854 A CZ 9854A CZ 5498 A CZ5498 A CZ 5498A CZ 5498 A3 CZ5498 A3 CZ 5498A3
Authority
CZ
Czechia
Prior art keywords
inhibitors
comprised
preparation
pharmaceutical composition
farnesyl transferase
Prior art date
Application number
CZ9854A
Other languages
English (en)
Other versions
CZ291620B6 (cs
Inventor
Alain Commercon
Brun Alain Le
Patrick Mailliet
Jean-Francois Peyronel
Fabienne Sounigo-Thompson
Alain Truchon
Martine Zucco
Original Assignee
Rhone-Poulenc Rorer S. A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone-Poulenc Rorer S. A. filed Critical Rhone-Poulenc Rorer S. A.
Publication of CZ5498A3 publication Critical patent/CZ5498A3/cs
Publication of CZ291620B6 publication Critical patent/CZ291620B6/cs

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C07D209/72—4,7-Endo-alkylene-iso-indoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CZ199854A 1995-07-10 1996-07-08 Benzoperhydroindoly, způsob jejich přípravy a farmaceutické kompozice tyto benzoperhydroindoly obsahující CZ291620B6 (cs)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9508296A FR2736641B1 (fr) 1995-07-10 1995-07-10 Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent

Publications (2)

Publication Number Publication Date
CZ5498A3 true CZ5498A3 (cs) 1998-04-15
CZ291620B6 CZ291620B6 (cs) 2003-04-16

Family

ID=9480830

Family Applications (1)

Application Number Title Priority Date Filing Date
CZ199854A CZ291620B6 (cs) 1995-07-10 1996-07-08 Benzoperhydroindoly, způsob jejich přípravy a farmaceutické kompozice tyto benzoperhydroindoly obsahující

Country Status (32)

Country Link
US (1) US5936097A (cs)
EP (1) EP0839133B1 (cs)
JP (1) JPH11511123A (cs)
KR (1) KR19990028856A (cs)
CN (1) CN1096448C (cs)
AR (1) AR003143A1 (cs)
AT (1) ATE185341T1 (cs)
AU (1) AU712194B2 (cs)
BR (1) BR9609440A (cs)
CA (1) CA2224414A1 (cs)
CO (1) CO4700457A1 (cs)
CZ (1) CZ291620B6 (cs)
DE (1) DE69604588T2 (cs)
DK (1) DK0839133T3 (cs)
EA (1) EA000797B1 (cs)
ES (1) ES2139373T3 (cs)
FR (1) FR2736641B1 (cs)
GR (1) GR3031409T3 (cs)
IL (1) IL122812A (cs)
MA (1) MA23929A1 (cs)
MX (1) MX9800262A (cs)
MY (1) MY114792A (cs)
NO (1) NO309565B1 (cs)
NZ (1) NZ313211A (cs)
PE (1) PE11898A1 (cs)
PL (1) PL324430A1 (cs)
SK (1) SK282250B6 (cs)
TN (1) TNSN96098A1 (cs)
TW (1) TW438792B (cs)
UY (1) UY24276A1 (cs)
WO (1) WO1997003050A1 (cs)
ZA (1) ZA965868B (cs)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6013662A (en) 1996-12-30 2000-01-11 Rhone-Poulenc Rorer S.A. Farnesyl transferase inhibitors, their preparation, the pharmaceutical compositions which contain them and their use in the preparation of medicaments
FR2757855B1 (fr) * 1996-12-30 1999-01-29 Rhone Poulenc Rorer Sa Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent
US6124465A (en) * 1997-11-25 2000-09-26 Rhone-Poulenc S.A. Farnesyl transferase inhibitors, their preparation, the pharmaceutical compositions which contain them and their use in the preparation of medicaments
EP1042329A1 (fr) * 1997-12-23 2000-10-11 Aventis Pharma S.A. Nouveaux inhibiteurs de farnesyle transferase, leur preparation, les compositions pharmaceutiques qui les contiennent et leur utilisation pour la preparation de medicaments
FR2772764B1 (fr) * 1997-12-23 2000-01-14 Rhone Poulenc Rorer Sa Nouveaux inhibiteurs de farnesyle transferase, leur preparation, les compositions pharmaceutiques qui les contiennent et leur utilisation pour la preparation de medicaments
FR2787327B1 (fr) * 1998-12-21 2003-01-17 Aventis Pharma Sa Compositions contenant des inhibiteurs de farnesyle transferase
FR2796641B1 (fr) 1999-07-22 2001-09-21 Aventis Pharma Sa Nouveau procede de preparation de composes benzoperhydroisoindole
US20020177575A1 (en) * 2001-05-04 2002-11-28 Ward Wakeland Identification of farnesyl-protein transferase as a target for systemic lupus erythematosus therapies
ATE550019T1 (de) 2005-05-17 2012-04-15 Merck Sharp & Dohme Cis-4-ä(4-chlorophenyl)sulfonylü-4-(2,5- difluorophenyl)cyclohexanepropansäure zur behandlug von krebs
PE20070335A1 (es) 2005-08-30 2007-04-21 Novartis Ag Benzimidazoles sustituidos y metodos para su preparacion
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
KR101464385B1 (ko) 2006-04-19 2014-11-21 노파르티스 아게 6-o-치환된 벤즈옥사졸 및 벤조티아졸 화합물, 및 csf-1r 신호전달의 억제 방법
AU2007300627B2 (en) 2006-09-22 2012-02-16 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
BRPI0806245B1 (pt) 2007-01-10 2022-01-25 Msd Italia S.R.L. Compostos de fórmula i e seus usos
CN101679266B (zh) 2007-03-01 2015-05-06 诺华股份有限公司 Pim激酶抑制剂及其应用方法
AU2008254425A1 (en) 2007-05-21 2008-11-27 Novartis Ag CSF-1R inhibitors, compositions, and methods of use
WO2009002495A1 (en) 2007-06-27 2008-12-31 Merck & Co., Inc. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
US7932036B1 (en) 2008-03-12 2011-04-26 Veridex, Llc Methods of determining acute myeloid leukemia response to treatment with farnesyltransferase
EP2413932A4 (en) 2009-04-01 2012-09-19 Merck Sharp & Dohme HAMMER OF ACT ACTIVITY
US8765747B2 (en) 2009-06-12 2014-07-01 Dana-Farber Cancer Institute, Inc. Fused 2-aminothiazole compounds
CA2777043C (en) 2009-10-14 2015-12-15 Schering Corporation Substituted piperidines that increase p53 activity and the uses thereof
EP2937345B1 (en) 2009-12-29 2018-03-21 Dana-Farber Cancer Institute, Inc. Type ii raf kinase inhibitors
BR112012023021A2 (pt) 2010-03-16 2016-05-31 Dana Farber Cancer Inst Inc compostos de indazol e seus usos
EP2584903B1 (en) 2010-06-24 2018-10-24 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
AU2011282614B2 (en) 2010-07-28 2015-11-26 Janssen Pharmaceutica Nv Methods of determining Acute Myeloid Leukemia response to treatment with farnesyltransferase inhibitors
CN103068980B (zh) 2010-08-02 2017-04-05 瑟纳治疗公司 使用短干扰核酸(siNA)的RNA干扰介导的联蛋白(钙粘蛋白关联蛋白质),β1(CTNNB1)基因表达的抑制
RU2745848C2 (ru) 2010-08-17 2021-04-01 Сирна Терапьютикс, Инк. ОПОСРЕДУЕМОЕ РНК-ИНТЕРФЕРЕНЦИЕЙ ИНГИБИРОВАНИЕ ЭКСПРЕССИИ ГЕНОВ ВИРУСА ГЕПАТИТА B (HBV) С ПРИМЕНЕНИЕМ МАЛОЙ ИНТЕРФЕРИРУЮЩЕЙ НУКЛЕИНОВОЙ КИСЛОТЫ (миНК)
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
EP2613782B1 (en) 2010-09-01 2016-11-02 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
WO2012058210A1 (en) 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
WO2012087772A1 (en) 2010-12-21 2012-06-28 Schering Corporation Indazole derivatives useful as erk inhibitors
WO2012143879A1 (en) 2011-04-21 2012-10-26 Piramal Healthcare Limited A crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
EP2770987B1 (en) 2011-10-27 2018-04-04 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
JP6106685B2 (ja) 2011-11-17 2017-04-05 ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド C−jun−n−末端キナーゼ(jnk)の阻害剤
EP3919620A1 (en) 2012-05-02 2021-12-08 Sirna Therapeutics, Inc. Short interfering nucleic acid (sina) compositions
CA2882950A1 (en) 2012-09-28 2014-04-03 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
EP2909194A1 (en) 2012-10-18 2015-08-26 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
US10000483B2 (en) 2012-10-19 2018-06-19 Dana-Farber Cancer Institute, Inc. Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof
USRE48175E1 (en) 2012-10-19 2020-08-25 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
SMT201700595T1 (it) 2012-11-28 2018-03-08 Merck Sharp & Dohme Composizioni e metodi per trattare il cancro
WO2014100065A1 (en) 2012-12-20 2014-06-26 Merck Sharp & Dohme Corp. Substituted imidazopyridines as hdm2 inhibitors
WO2014120748A1 (en) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
WO2015058126A1 (en) 2013-10-18 2015-04-23 Syros Pharmaceuticals, Inc. Heteroaromatic compounds useful for the treatment of prolferative diseases
AU2014337044A1 (en) 2013-10-18 2016-05-05 Dana-Farber Cancer Institute, Inc. Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7)
US9862688B2 (en) 2014-04-23 2018-01-09 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged janus kinase inhibitors and uses thereof
WO2015164614A1 (en) 2014-04-23 2015-10-29 Dana-Farber Cancer Institute, Inc. Janus kinase inhibitors and uses thereof
JO3589B1 (ar) 2014-08-06 2020-07-05 Novartis Ag مثبطات كيناز البروتين c وطرق استخداماتها
US10870651B2 (en) 2014-12-23 2020-12-22 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
CN107427521B (zh) 2015-03-27 2021-08-03 达纳-法伯癌症研究所股份有限公司 细胞周期蛋白依赖性激酶的抑制剂
CA2986441A1 (en) 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
US10471055B2 (en) 2015-08-17 2019-11-12 Kura Oncology, Inc. Methods of treating cancer patients with farnesyltransferase inhibitors
WO2017044858A2 (en) 2015-09-09 2017-03-16 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
JOP20190055A1 (ar) 2016-09-26 2019-03-24 Merck Sharp & Dohme أجسام مضادة ضد cd27
US10975084B2 (en) 2016-10-12 2021-04-13 Merck Sharp & Dohme Corp. KDM5 inhibitors
HRP20210544T1 (hr) 2016-11-03 2021-08-20 Kura Oncology, Inc. Inhibitori farneziltransferaze za uporabu u liječenju raka
JP7160833B2 (ja) 2017-04-13 2022-10-25 サイロパ ビー.ブイ. 抗sirpアルファ抗体
EP3706742B1 (en) 2017-11-08 2023-03-15 Merck Sharp & Dohme LLC Prmt5 inhibitors
WO2019094312A1 (en) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Prmt5 inhibitors
WO2019113269A1 (en) 2017-12-08 2019-06-13 Kura Oncology, Inc. Methods of treating cancer patients with farnesyltransferase inhibitors
WO2019148412A1 (en) 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anti-pd-1/lag3 bispecific antibodies
EP3810132A4 (en) 2018-06-25 2022-06-22 Dana-Farber Cancer Institute, Inc. TAIRE FAMILY KINASE INHIBITORS AND RELATED USES
WO2020033282A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
CA3108388A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
WO2020033285A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
EP3833667B1 (en) 2018-08-07 2024-03-13 Merck Sharp & Dohme LLC Prmt5 inhibitors
CN113164477A (zh) 2018-12-14 2021-07-23 达纳-法伯癌症研究所股份有限公司 C-jun-n-末端激酶的吡唑并吡啶抑制剂及其用途
EP3902542A4 (en) 2018-12-28 2022-09-07 Dana-Farber Cancer Institute, Inc. CYCLIN DEPENDENT KINASE 7 INHIBITORS AND USES THEREOF
US20220143006A1 (en) 2019-03-15 2022-05-12 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
ES3022307T3 (en) 2019-12-17 2025-05-28 Merck Sharp & Dohme Llc Prmt5 inhibitors
EP4076460B1 (en) 2019-12-17 2026-01-21 Merck Sharp & Dohme LLC 1,4-dihydro-2h-spiro[isoquinoline-3,4'-piperidine derivatives as prmt5 inhibitors for the treatment of cancer
EP4303246A1 (de) 2022-07-04 2024-01-10 Covestro Deutschland AG Polyisocyanatgemisch
WO2024180169A1 (en) 2023-03-02 2024-09-06 Carcimun Biotech Gmbh Means and methods for diagnosing cancer and/or an acute inflammatory disease
DE212025000115U1 (de) 2024-07-30 2026-06-18 Sairopa B.V. Anti-SIRP Alpha-Antikörperformulierungen und ihre Verwendung

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2492372A1 (fr) * 1980-10-21 1982-04-23 Cird Dihydroxy-1,8 anthrones-9 substituees en position 10 et leur utilisation en medecine humaine ou veterinaire et en cosmetique
KR100362338B1 (ko) * 1993-11-05 2003-04-08 워너-램버트 캄파니 단백질:파르네실트랜스퍼라아제의치환디-및트리펩티드억제제

Also Published As

Publication number Publication date
PE11898A1 (es) 1998-03-15
CO4700457A1 (es) 1998-12-29
NZ313211A (en) 1999-11-29
AR003143A1 (es) 1998-07-08
CZ291620B6 (cs) 2003-04-16
IL122812A0 (en) 1998-08-16
FR2736641B1 (fr) 1997-08-22
TW438792B (en) 2001-06-07
AU712194B2 (en) 1999-10-28
UY24276A1 (es) 2001-10-25
MA23929A1 (fr) 1997-04-01
MX9800262A (es) 1998-04-30
US5936097A (en) 1999-08-10
EP0839133B1 (fr) 1999-10-06
TNSN96098A1 (fr) 2005-03-15
MY114792A (en) 2003-01-31
WO1997003050A1 (fr) 1997-01-30
FR2736641A1 (fr) 1997-01-17
SK2698A3 (en) 1998-07-08
CN1190389A (zh) 1998-08-12
DK0839133T3 (da) 2000-04-17
NO980094L (no) 1998-02-17
KR19990028856A (ko) 1999-04-15
PL324430A1 (en) 1998-05-25
SK282250B6 (sk) 2001-12-03
ES2139373T3 (es) 2000-02-01
CA2224414A1 (fr) 1997-01-30
GR3031409T3 (en) 2000-01-31
NO309565B1 (no) 2001-02-19
EA199800118A1 (ru) 1998-08-27
ZA965868B (en) 1997-01-29
EA000797B1 (ru) 2000-04-24
DE69604588T2 (de) 2000-05-18
CN1096448C (zh) 2002-12-18
IL122812A (en) 2001-04-30
DE69604588D1 (en) 1999-11-11
ATE185341T1 (de) 1999-10-15
NO980094D0 (no) 1998-01-09
EP0839133A1 (fr) 1998-05-06
JPH11511123A (ja) 1999-09-28
AU6522496A (en) 1997-02-10
BR9609440A (pt) 1999-06-29

Similar Documents

Publication Publication Date Title
ZA965750B (en) Farnesyl transferase inhibitors their preparation and pharmaceutical composition comprising them
ZA965868B (en) Farnesyl transferase inhibitors their preparation and pharmaceutical compositions comprising them
AU4543696A (en) Novel farnesyl transferase inhibitors, preparation thereof and pharmaceutical compositions containing same
AU4722796A (en) Novel farnesyl transferase inhibitors, preparation thereof, and pharmaceutical compositions containing same
AU4722896A (en) Novel farnesyl transferase inhibitors, preparation thereof, and pharmaceutical compositions containing same
HUP9900185A3 (en) Farnesyl protein transferase inhibiting (imidazol-5-yl)methyl-2-quinolinone derivatives, their preparation, pharmaceutical compositions containing them and their use
HUP9802857A3 (en) 4-mercaptopyrrolidine derivatives as farnesyl transferase inhibitors, process for producing them and pharmaceutical compositions containing them
IL117580A0 (en) Inhibitors of farnesyl-protein transferase and pharmaceutical compositions containing them
IL119466A (en) Thrombin inhibitors, their preparation and pharmaceutical compositions containing them
AP2001002270A0 (en) Metalloproteinaise inhibitors pharmaceutical compositions containing them and their pharmaceeutical uses and methods and intermediates useful for their preparation
IL117598A (en) Quinazoline derivatives, process for their preparation and pharmaceutical compositions containing them
ZA9610299B (en) Pyrazole derivatives process for their preparation and pharmaceutical compositions in which they are present
HUP9802315A3 (en) Thrombin inhibitors, process for producing them and use of them for producing pharmaceutical compositions
HUP0001747A3 (en) 1h-benzo[+]isoindole derivatives as farnesyl transferase inhibitor, process for producing them and use of them for process pharmaceutical compositions
HUT70544A (en) Heteroaryl-amines as acetyl-cholinesterase inhibitors, pharmaceutical compositions comprising them and process for their preparation
IL119559A0 (en) Purin -6- one derivatives their preparation and pharmaceutical compositions containing them
CZ129596A3 (en) Oxazolidinone derivative, process of its preparation and pharmaceutical composition containing thereof
IL119316A0 (en) Hydroxypyridinones their preparation and pharmaceutical compositions containing them
HUP9602635A3 (en) 4-aciloxy-benzenesulfonamide derivatives, process for their preparation and pharmaceutical compositions containing them
HUP0203054A3 (en) Farnesyl protein transferase inhibitors, pharmaceutical compositions containing them and their use
IL117554A0 (en) Imidazoquinazolines their preparation and pharmaceutical compositions containing them
HUP9802408A3 (en) Naphthyl and dihydronaphthyl-derivatives, and pharmaceutical compositions, containing them
HUP9801386A3 (en) Indazolecarboxamide derivatives, preparation thereof and pharmaceutical compositions containing them
CZ346595A3 (en) Substituted derivatives of 4-phenylthiazoles, process of their preparation and pharmaceutical compositions containing thereof
CZ92295A3 (en) Boronpeptide derivatives, process of their preparation and pharmaceutical composition containing thereof

Legal Events

Date Code Title Description
PD00 Pending as of 2000-06-30 in czech republic
MM4A Patent lapsed due to non-payment of fee

Effective date: 19960708